Related Experiment Video
Updated: Jun 20, 2026
A Method for Murine Islet Isolation and Subcapsular Kidney Transplantation
Published on: April 13, 2011
Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient
Indraneel Banerjee1, Diva De Leon2, Mark J Dunne3,4
1Paediatric Endocrinology, Central Manchester University Hospitals NHS Foundation Trust (CMFT) and The University of Manchester, Oxford Road, Manchester, M13 9PT, UK.
Abstract:
We have recently published on the limited effectiveness of sirolimus as a treatment option for hypoglycaemia as a consequence of hyperinsulinism. Our data oppose the view that mTOR inhibitors provide new opportunities for the treatment of patients with hyperinsulinism. We are not convinced by the argument that any benefit for some patients outweighs the potential and later long-term problems that accompany mTOR inhibition in the neonate. We also express the opinion that caution must be taken when repurposing/repositioning therapies in the field of rare disease.
Insights
Sirolimus shows limited effectiveness for treating hyperinsulinism-induced hypoglycemia. mTOR inhibitors may pose long-term risks, especially in neonates, warranting caution in rare disease therapy repositioning.
Area of Science:
- Endocrinology
- Pharmacology
- Rare Diseases
Background:
- Hyperinsulinism is a condition characterized by excessive insulin secretion, leading to hypoglycemia.
- Sirolimus, an mTOR inhibitor, has been explored as a treatment for hyperinsulinism.
- Previous research suggested potential benefits of mTOR inhibitors in managing hyperinsulinism.
Discussion:
- Our findings indicate limited effectiveness of sirolimus in treating hypoglycemia caused by hyperinsulinism.
- The data challenge the notion that mTOR inhibitors offer significant new therapeutic avenues for hyperinsulinism.
- Concerns exist regarding the long-term adverse effects of mTOR inhibition in neonates, potentially outweighing short-term benefits.
Key Insights:
- Sirolimus demonstrates restricted efficacy for hyperinsulinism-related hypoglycemia.
- mTOR inhibitors are not a universally beneficial treatment for hyperinsulinism.
- Neonatal exposure to mTOR inhibitors carries potential long-term risks.
Outlook:
- Further research is needed to explore safer and more effective treatments for hyperinsulinism.
- Caution is advised when repurposing existing drugs for rare diseases like hyperinsulinism.
- A thorough risk-benefit assessment is crucial before implementing mTOR inhibitors in neonatal care.
